Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma
Huijuan Wang(Zhengzhou University), Zhiyong Ma(Ministry of Education of the People's Republic of China), Qiming Wang(Hunan Cancer Hospital), Guanbin Qi(Zhengzhou University), Peng Li, Qing-Xia Fan(First Affiliated Hospital of Zhengzhou University), Hui Zhu(Sun Yat-sen University), Guowei Zhang(Central Hospital of Wuhan)
Cited by 0
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
|Cell Death and Disease|2023|130